These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19877986)

  • 1. Observation of QTc prolongation in an adolescent girl during fluvoxamine pharmacotherapy.
    Brzozowska A; Werner B
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):591-2. PubMed ID: 19877986
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvoxamine for the treatment of anxiety disorders in children and adolescents.
    Isaacs E
    N Engl J Med; 2001 Aug; 345(6):466-7. PubMed ID: 11496864
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical impact of fluvoxamine-mediated long QTU syndrome.
    Nia AM; Dahlem KM; Gassanov N; Hungerbühler H; Fuhr U; Er F
    Eur J Clin Pharmacol; 2012 Jan; 68(1):109-11. PubMed ID: 21713517
    [No Abstract]   [Full Text] [Related]  

  • 4. Extended-release fluvoxamine (Luvox CR).
    Med Lett Drugs Ther; 2008 Jun; 50(1289):50-1. PubMed ID: 18583947
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychopharmacologic Management of Anxiety in an Adolescent with Congenital Long QT Syndrome.
    Minton TB; Rosing J; Spar DS; Strawn JR; Garcia-Delgar B; Coffey BJ
    J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):485-9. PubMed ID: 27285068
    [No Abstract]   [Full Text] [Related]  

  • 6. Ecchymoses as an adverse effect of fluvoxamine treatment in an adolescent girl.
    Vlatka BM; Branka AM; Branimir M
    Gen Hosp Psychiatry; 2010; 32(4):e9-e10. PubMed ID: 20633737
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative study of QT prolongation with serotonin reuptake inhibitors.
    Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
    Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.
    N Engl J Med; 2001 Apr; 344(17):1279-85. PubMed ID: 11323729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
    Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.
    Reinblatt SP; DosReis S; Walkup JT; Riddle MA
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):119-26. PubMed ID: 19364290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine.
    Kohn Y; Weizman A; Apter A
    Int J Eat Disord; 2001 Jul; 30(1):113-7. PubMed ID: 11439417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine.
    Stirnimann G; Petitprez S; Abriel H; Schwick NG
    Europace; 2010 Feb; 12(2):282-3. PubMed ID: 19875396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity with selective serotonin reuptake inhibitors.
    Solomons K; Gooch S; Wong A
    Am J Psychiatry; 2005 Jun; 162(6):1225. PubMed ID: 15930079
    [No Abstract]   [Full Text] [Related]  

  • 14. [Customized pharmacotherapies in schizophrenia].
    Suzuki Y; Fukui N; Watanabe J; Ono S; Sugai T; Tsuneyama N; Someya T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):77-81. PubMed ID: 20491281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal Side Effects in the Baby of a Breastfeeding Woman Treated with Low-Dose Fluvoxamine.
    Uguz F
    J Hum Lact; 2015 Aug; 31(3):371-3. PubMed ID: 25896469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased libido in a woman treated with fluvoxamine: a case report.
    Hori H; Yoshimura R; Nakamura J
    Acta Psychiatr Scand; 2001 Apr; 103(4):312-4. PubMed ID: 11328247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine and mandibular dystonia.
    Chong SA
    Can J Psychiatry; 1995 Sep; 40(7):430-1. PubMed ID: 8548729
    [No Abstract]   [Full Text] [Related]  

  • 18. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine.
    Wilting I; Smals OM; Holwerda NJ; Meyboom RH; de Bruin ML; Egberts TC
    Am J Psychiatry; 2006 Feb; 163(2):325. PubMed ID: 16449492
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations.
    Yamazaki-Hashimoto Y; Nakamura Y; Ohara H; Cao X; Kitahara K; Izumi-Nakaseko H; Ando K; Yamazaki H; Ikeda T; Yamazaki J; Sugiyama A
    J Toxicol Sci; 2015 Feb; 40(1):33-42. PubMed ID: 25560394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.
    Beach SR; Kostis WJ; Celano CM; Januzzi JL; Ruskin JN; Noseworthy PA; Huffman JC
    J Clin Psychiatry; 2014 May; 75(5):e441-9. PubMed ID: 24922496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.